Physician profile
Amy Patel
NPI 1528491958
$4,411.30
in general payments reported to CMS, 2019-2025
48 companies · $895 in 2025
The $895 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $583 · 2023: $1,563 · 2024: $1,025 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.14 |
| Education | $300.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $785.58 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $606.27 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Ucb, INC. | $288.85 | 2021-2025 | Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $252.91 | 2022-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $243.09 | 2021-2025 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $157.05 | 2023-2025 | Gemtesa, Aptiom |
| Novo Nordisk INC | $146.97 | 2022-2025 | Wegovy |
| Pfizer INC. | $140.93 | 2021-2025 | |
| Abbvie INC. | $138.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $114.95 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $113.14 | 2022-2025 | |
| Verona Pharma, INC. | $105.73 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $98.19 | 2021-2025 | Xarelto, Invega Sustenna |
| Acadia Pharmaceuticals INC | $94.72 | 2021-2024 | Nuplazid |
| Shield Therapeutics INC | $69.91 | 2023-2024 | Accrufer |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.